Monday, August 8, 2011
Trius Therapeutics Inc., of San Diego, reached an agreement with the FDA, under the special protocol assessment (SPA) process, on the design of its second planned Phase III study for the intravenous and oral dosage forms of torezolid phosphate to treat acute bacterial skin and skin structure infections.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.